Supernus Pharmaceuticals (SUPN) Asset Writedowns and Impairment (2023 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Asset Writedowns and Impairment of $54.9 million for Q2 2026, up 2925.84% on a QoQ basis from $1.8 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $54.9 million in Q2 2026.
- Asset Writedowns and Impairment for Q2 2026 came in at $54.9 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $57.2 million (up 670.28% YoY), and the FY2025 annual result was $1.9 million, down 78.36% from the prior year.
- Asset Writedowns and Impairment advanced to $54.9 million in Q2 2026, from $1.8 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $54.9 million in Q2 2026 and troughed at -$239000.0 in Q3 2025.
- A 4-year average of $8.7 million and a median of $1.0 million in 2024 frame the typical range for Asset Writedowns and Impairment.
- The widest annual swing landed in 2025, when Asset Writedowns and Impairment slumped 724.14%; it then surged 231.81% in 2026.
- A 4-year view of Asset Writedowns and Impairment shows it stood at $20.2 million in 2023, then slumped by 65.81% to $6.9 million in 2024, then slumped by 89.89% to $698000.0 in 2025, then soared by 7768.05% to $54.9 million in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $54.9 million in Q2 2026, $1.8 million in Q1 2026, and $698000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.92 Mn |
| Jun 30, 2026 | 54.92 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Dec 31, 2025 | 672,000.00 |
| Dec 31, 2025 | 672,000.00 |
| Sep 30, 2025 | -239,000.00 |
| Sep 30, 2025 | -239,000.00 |
| Jun 30, 2025 | 920,000.00 |
| Jun 30, 2025 | 920,000.00 |
| Mar 31, 2025 | 547,000.00 |
| Mar 31, 2025 | 547,000.00 |
| Dec 31, 2024 | 6.88 Mn |
| Dec 31, 2024 | 6.88 Mn |
| Sep 30, 2024 | -29,000.00 |
| Sep 30, 2024 | -29,000.00 |
| Jun 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 730,000.00 |
| Mar 31, 2024 | 730,000.00 |